Share Price and Basic Stock Data
Last Updated: February 6, 2026, 2:30 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Astec Lifesciences Ltd operates in the agrochemicals and pesticides sector, with a current market capitalization of ₹1,318 Cr. The company’s stock price stood at ₹586. Revenue trends have shown volatility, with sales reported at ₹628 Cr for FY 2023, declining from ₹677 Cr in FY 2022. The trailing twelve months (TTM) revenue is ₹378 Cr, reflecting ongoing challenges in maintaining sales momentum. Quarterly sales figures indicate fluctuations, with a high of ₹200 Cr in September 2022, followed by a low of ₹51 Cr in December 2023. This inconsistency in revenue generation raises concerns about the company’s ability to stabilize its market position amidst competitive pressures. The agrochemicals sector typically experiences seasonal demand, which may contribute to these revenue swings. Overall, Astec’s revenue performance highlights the need for strategic adjustments to enhance market share and stabilize income streams.
Profitability and Efficiency Metrics
Astec Lifesciences Ltd has reported significant challenges in profitability, with a net profit of -₹114 Cr for the TTM period, down from a profit of ₹26 Cr in FY 2023. The operating profit margin (OPM) has dipped to -9%, a stark contrast to the 12% reported in FY 2023, indicating a deterioration in operational efficiency. Quarterly operating profits have fluctuated, with the most recent quarter (September 2023) reporting a loss of ₹3 Cr. The interest coverage ratio (ICR) stood at -1.65x, suggesting that the company struggles to meet its interest obligations. This low ratio reflects a critical concern regarding financial stability, especially when compared to healthy sector norms. Additionally, the return on equity (ROE) of 45.3% is notable; however, this figure is misleading given the context of negative net profits. Furthermore, the cash conversion cycle (CCC) of 237 days indicates inefficiencies in managing working capital, which could hamper future profitability.
Balance Sheet Strength and Financial Ratios
Astec Lifesciences Ltd’s balance sheet reveals significant financial stress, with total borrowings reported at ₹367 Cr against reserves of ₹392 Cr, indicating a precarious financial position. The total debt-to-equity ratio stands at 2.36x, suggesting a highly leveraged structure that poses risks in adverse market conditions. The company reported fixed assets of ₹499 Cr, but the depreciation expense has been consistently high, recorded at ₹44 Cr for FY 2025. This depreciation may further impact the profitability outlook. The book value per share has declined to ₹119.70, down from ₹214.00 in FY 2023, reflecting a reduction in shareholder equity. The current ratio is recorded at 0.93, below the ideal benchmark of 1, indicating potential liquidity issues. Such financial ratios highlight the need for Astec to reassess its capital structure and operational efficiency to enhance its financial resilience.
Shareholding Pattern and Investor Confidence
Astec Lifesciences’ shareholding pattern reflects a strong promoter commitment, with promoters holding 72.42% of the company as of September 2025. This significant stake can be seen as a stabilizing factor for investor confidence. However, foreign institutional investors (FIIs) have exited, with their holding declining from 2.19% in December 2022 to 0% by September 2025, signaling potential concerns regarding the company’s future prospects. Domestic institutional investors (DIIs) hold 4.01%, a modest presence that may limit institutional support. The public shareholding has slightly decreased to 23.57%, indicating a potential reduction in retail investor interest. The total number of shareholders stands at 18,276, suggesting a relatively stable investor base, albeit one that may be apprehensive given the recent financial performance. The exit of FIIs, in particular, could reflect broader market sentiments about the company’s viability in the agrochemicals sector, which is characterized by intense competition and regulatory scrutiny.
Outlook, Risks, and Final Insight
The outlook for Astec Lifesciences Ltd remains challenging due to its current financial performance and market conditions. Key strengths include the high promoter holding, which may provide stability, and the potential for operational improvements. However, the risks are pronounced, including declining revenues, negative profitability, and high leverage, which could limit growth opportunities and investor confidence. The company’s ability to innovate and adapt to market demands will be crucial for recovery. If Astec can successfully implement cost-control measures, enhance operational efficiencies, and stabilize revenues, it may return to a growth trajectory. Conversely, failure to address these challenges could lead to further declines in market position and financial health. In this context, strategic initiatives focusing on product development and market expansion will be vital for securing Astec’s future in the competitive agrochemical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Epigral Ltd | 4,271 Cr. | 990 | 2,114/903 | 12.7 | 487 | 0.60 % | 24.9 % | 22.3 % | 10.0 |
| Dharmaj Crop Guard Ltd | 817 Cr. | 242 | 391/165 | 16.8 | 131 | 0.00 % | 12.0 % | 9.28 % | 10.0 |
| Bhaskar Agrochemicals Ltd | 70.3 Cr. | 135 | 149/56.6 | 12.6 | 40.0 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
| Bhagiradha Chemicals & Industries Ltd | 2,951 Cr. | 228 | 331/198 | 111 | 54.9 | 0.07 % | 7.44 % | 4.91 % | 1.00 |
| Best Agrolife Ltd | 709 Cr. | 20.0 | 35.8/16.3 | 55.4 | 22.8 | 0.96 % | 12.9 % | 9.95 % | 1.00 |
| Industry Average | 10,666.50 Cr | 1,097.44 | 30.13 | 369.04 | 0.44% | 15.21% | 19.87% | 6.67 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 127 | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 |
| Expenses | 105 | 122 | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 |
| Operating Profit | 12 | 5 | 3 | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 | -7 | 4 |
| OPM % | 10% | 4% | 2% | -3% | -36% | 8% | -67% | -20% | -6% | 5% | -12% | -9% | 3% |
| Other Income | 4 | 3 | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | -1 |
| Interest | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 |
| Depreciation | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 |
| Profit before tax | 1 | -6 | -11 | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 | -24 | -16 |
| Tax % | 31% | -20% | -26% | -24% | -24% | 4% | -36% | 0% | 61% | 3% | 0% | 0% | 0% |
| Net Profit | 1 | -5 | -8 | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 | -24 | -16 |
| EPS in Rs | 0.38 | -2.22 | -3.66 | -6.00 | -10.86 | -0.43 | -17.73 | -17.21 | -18.03 | -7.18 | -14.75 | -10.96 | -7.05 |
Last Updated: February 6, 2026, 3:46 pm
Below is a detailed analysis of the quarterly data for Astec Lifesciences Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 125.00 Cr.. The value appears strong and on an upward trend. It has increased from 74.00 Cr. (Sep 2025) to 125.00 Cr., marking an increase of 51.00 Cr..
- For Expenses, as of Dec 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 80.00 Cr. (Sep 2025) to 121.00 Cr., marking an increase of 41.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from -7.00 Cr. (Sep 2025) to 4.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Dec 2025, the value is 3.00%. The value appears strong and on an upward trend. It has increased from -9.00% (Sep 2025) to 3.00%, marking an increase of 12.00%.
- For Other Income, as of Dec 2025, the value is -1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Sep 2025) to -1.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Dec 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.00 Cr. (Sep 2025) to 7.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Dec 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Sep 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Dec 2025, the value is -16.00 Cr.. The value appears strong and on an upward trend. It has increased from -24.00 Cr. (Sep 2025) to -16.00 Cr., marking an increase of 8.00 Cr..
- For Tax %, as of Dec 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00%.
- For Net Profit, as of Dec 2025, the value is -16.00 Cr.. The value appears strong and on an upward trend. It has increased from -24.00 Cr. (Sep 2025) to -16.00 Cr., marking an increase of 8.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is -7.05. The value appears strong and on an upward trend. It has increased from -10.96 (Sep 2025) to -7.05, marking an increase of 3.91.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 207 | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 378 |
| Expenses | 171 | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 396 |
| Operating Profit | 35 | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -18 |
| OPM % | 17% | 20% | 14% | 21% | 19% | 18% | 16% | 20% | 23% | 12% | -1% | -17% | -5% |
| Other Income | -0 | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 4 |
| Interest | 9 | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 40 |
| Depreciation | 15 | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 |
| Profit before tax | 11 | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -98 |
| Tax % | 22% | -17% | 59% | 33% | 37% | 36% | 23% | 27% | 26% | 27% | -24% | -4% | |
| Net Profit | 9 | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -114 |
| EPS in Rs | 4.09 | 6.66 | 2.24 | 8.57 | 15.65 | 16.03 | 21.21 | 29.04 | 40.12 | 11.41 | -20.95 | -60.16 | -50.92 |
| Dividend Payout % | 21% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 66.67% | -66.67% | 280.00% | 84.21% | 2.86% | 33.33% | 35.42% | 38.46% | -71.11% | -280.77% | -187.23% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | 346.67% | -195.79% | -81.35% | 30.48% | 2.08% | 3.04% | -109.57% | -209.66% | 93.54% |
Astec Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -6% |
| 3 Years: | -17% |
| TTM: | 5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -7% |
| 3 Years: | -23% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 0% |
| 3 Years: | -14% |
| Last Year: | -45% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
| Reserves | 95 | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 392 |
| Borrowings | 83 | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 367 |
| Other Liabilities | 88 | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total Liabilities | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 883 |
| Fixed Assets | 132 | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 500 |
| CWIP | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 146 | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 383 |
| Total Assets | 284 | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 883 |
Below is a detailed analysis of the balance sheet data for Astec Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 392.00 Cr.. The value appears strong and on an upward trend. It has increased from 215.00 Cr. (Mar 2025) to 392.00 Cr., marking an increase of 177.00 Cr..
- For Borrowings, as of Sep 2025, the value is 367.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 555.00 Cr. (Mar 2025) to 367.00 Cr., marking a decrease of 188.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 102.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.00 Cr. (Mar 2025) to 102.00 Cr., marking an increase of 10.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 883.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 881.00 Cr. (Mar 2025) to 883.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 500.00 Cr.. The value appears strong and on an upward trend. It has increased from 499.00 Cr. (Mar 2025) to 500.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 21.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 383.00 Cr.. The value appears strong and on an upward trend. It has increased from 361.00 Cr. (Mar 2025) to 383.00 Cr., marking an increase of 22.00 Cr..
- For Total Assets, as of Sep 2025, the value is 883.00 Cr.. The value appears strong and on an upward trend. It has increased from 881.00 Cr. (Mar 2025) to 883.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (392.00 Cr.) exceed the Borrowings (367.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -48.00 | -39.00 | -95.00 | -64.00 | -56.00 | -100.00 | -14.00 | -75.00 | -125.00 | -264.00 | -500.00 | -621.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 91 | 142 | 126 | 135 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 |
| Inventory Days | 192 | 147 | 177 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 |
| Days Payable | 114 | 179 | 169 | 116 | 155 | 83 | 218 | 137 | 179 | 161 | 102 | 100 |
| Cash Conversion Cycle | 168 | 109 | 134 | 152 | 89 | 142 | 25 | 100 | 145 | 197 | 256 | 237 |
| Working Capital Days | 23 | 19 | -28 | 1 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 |
| ROCE % | 11% | 20% | 12% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 526,867 | 0.05 | 37.14 | 468,589 | 2025-12-08 04:51:58 | 12.44% |
| ICICI Prudential Commodities Fund | 128,411 | 0.27 | 9.05 | 112,360 | 2025-12-08 04:51:58 | 14.29% |
| ICICI Prudential MidCap Fund | 18,107 | 0.02 | 1.28 | 15,844 | 2025-12-08 00:51:54 | 14.28% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.87 | 33.23 |
| Diluted EPS (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| Cash EPS (Rs.) | -46.40 | -5.42 | 30.22 | 63.39 | 46.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 119.70 | 188.44 | 214.00 | 202.40 | 157.91 |
| Revenue From Operations / Share (Rs.) | 194.43 | 233.66 | 320.40 | 345.23 | 283.28 |
| PBDIT / Share (Rs.) | -30.89 | -0.13 | 45.56 | 83.96 | 61.00 |
| PBIT / Share (Rs.) | -53.18 | -18.62 | 28.39 | 66.43 | 47.90 |
| PBT / Share (Rs.) | -71.89 | -31.49 | 17.82 | 61.81 | 45.47 |
| Net Profit / Share (Rs.) | -68.69 | -23.91 | 13.05 | 45.86 | 33.22 |
| NP After MI And SOA / Share (Rs.) | -68.71 | -23.93 | 13.04 | 45.85 | 33.21 |
| PBDIT Margin (%) | -15.88 | -0.05 | 14.21 | 24.31 | 21.53 |
| PBIT Margin (%) | -27.35 | -7.97 | 8.86 | 19.24 | 16.90 |
| PBT Margin (%) | -36.97 | -13.47 | 5.56 | 17.90 | 16.05 |
| Net Profit Margin (%) | -35.32 | -10.23 | 4.07 | 13.28 | 11.72 |
| NP After MI And SOA Margin (%) | -35.33 | -10.24 | 4.06 | 13.28 | 11.72 |
| Return on Networth / Equity (%) | -57.40 | -12.70 | 6.09 | 22.66 | 21.03 |
| Return on Capital Employeed (%) | -20.22 | -6.32 | 12.28 | 32.05 | 26.40 |
| Return On Assets (%) | -15.28 | -4.81 | 2.61 | 10.02 | 9.60 |
| Long Term Debt / Equity (X) | 1.19 | 0.53 | 0.02 | 0.00 | 0.12 |
| Total Debt / Equity (X) | 2.36 | 1.34 | 0.81 | 0.70 | 0.60 |
| Asset Turnover Ratio (%) | 0.41 | 0.46 | 0.66 | 0.85 | 0.88 |
| Current Ratio (X) | 0.93 | 1.00 | 0.94 | 1.05 | 1.03 |
| Quick Ratio (X) | 0.49 | 0.51 | 0.38 | 0.67 | 0.69 |
| Inventory Turnover Ratio (X) | 2.14 | 1.30 | 1.91 | 3.04 | 3.03 |
| Dividend Payout Ratio (NP) (%) | 0.00 | -6.26 | 11.50 | 3.26 | 4.51 |
| Dividend Payout Ratio (CP) (%) | 0.00 | -27.54 | 4.96 | 2.36 | 3.23 |
| Earning Retention Ratio (%) | 0.00 | 106.26 | 88.50 | 96.74 | 95.49 |
| Cash Earning Retention Ratio (%) | 0.00 | 127.54 | 95.04 | 97.64 | 96.77 |
| Interest Coverage Ratio (X) | -1.65 | -0.01 | 4.31 | 18.17 | 25.15 |
| Interest Coverage Ratio (Post Tax) (X) | -2.67 | -0.85 | 2.24 | 10.92 | 14.69 |
| Enterprise Value (Cr.) | 1875.49 | 2574.29 | 3049.60 | 3711.79 | 2144.94 |
| EV / Net Operating Revenue (X) | 4.92 | 5.62 | 4.85 | 5.49 | 3.87 |
| EV / EBITDA (X) | -30.96 | -9580.53 | 34.14 | 22.56 | 17.95 |
| MarketCap / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| Retention Ratios (%) | 0.00 | 106.26 | 88.49 | 96.73 | 95.48 |
| Price / BV (X) | 5.64 | 5.64 | 6.46 | 8.66 | 6.34 |
| Price / Net Operating Revenue (X) | 3.47 | 4.55 | 4.31 | 5.08 | 3.53 |
| EarningsYield | -0.10 | -0.02 | 0.01 | 0.02 | 0.03 |
After reviewing the key financial ratios for Astec Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Diluted EPS (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 5. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For Cash EPS (Rs.), as of Mar 25, the value is -46.40. This value is below the healthy minimum of 3. It has decreased from -5.42 (Mar 24) to -46.40, marking a decrease of 40.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 119.70. It has decreased from 188.44 (Mar 24) to 119.70, marking a decrease of 68.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 194.43. It has decreased from 233.66 (Mar 24) to 194.43, marking a decrease of 39.23.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -30.89. This value is below the healthy minimum of 2. It has decreased from -0.13 (Mar 24) to -30.89, marking a decrease of 30.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is -53.18. This value is below the healthy minimum of 0. It has decreased from -18.62 (Mar 24) to -53.18, marking a decrease of 34.56.
- For PBT / Share (Rs.), as of Mar 25, the value is -71.89. This value is below the healthy minimum of 0. It has decreased from -31.49 (Mar 24) to -71.89, marking a decrease of 40.40.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -68.69. This value is below the healthy minimum of 2. It has decreased from -23.91 (Mar 24) to -68.69, marking a decrease of 44.78.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -68.71. This value is below the healthy minimum of 2. It has decreased from -23.93 (Mar 24) to -68.71, marking a decrease of 44.78.
- For PBDIT Margin (%), as of Mar 25, the value is -15.88. This value is below the healthy minimum of 10. It has decreased from -0.05 (Mar 24) to -15.88, marking a decrease of 15.83.
- For PBIT Margin (%), as of Mar 25, the value is -27.35. This value is below the healthy minimum of 10. It has decreased from -7.97 (Mar 24) to -27.35, marking a decrease of 19.38.
- For PBT Margin (%), as of Mar 25, the value is -36.97. This value is below the healthy minimum of 10. It has decreased from -13.47 (Mar 24) to -36.97, marking a decrease of 23.50.
- For Net Profit Margin (%), as of Mar 25, the value is -35.32. This value is below the healthy minimum of 5. It has decreased from -10.23 (Mar 24) to -35.32, marking a decrease of 25.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -35.33. This value is below the healthy minimum of 8. It has decreased from -10.24 (Mar 24) to -35.33, marking a decrease of 25.09.
- For Return on Networth / Equity (%), as of Mar 25, the value is -57.40. This value is below the healthy minimum of 15. It has decreased from -12.70 (Mar 24) to -57.40, marking a decrease of 44.70.
- For Return on Capital Employeed (%), as of Mar 25, the value is -20.22. This value is below the healthy minimum of 10. It has decreased from -6.32 (Mar 24) to -20.22, marking a decrease of 13.90.
- For Return On Assets (%), as of Mar 25, the value is -15.28. This value is below the healthy minimum of 5. It has decreased from -4.81 (Mar 24) to -15.28, marking a decrease of 10.47.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 1.19. This value exceeds the healthy maximum of 1. It has increased from 0.53 (Mar 24) to 1.19, marking an increase of 0.66.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.36. This value exceeds the healthy maximum of 1. It has increased from 1.34 (Mar 24) to 2.36, marking an increase of 1.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.41. It has decreased from 0.46 (Mar 24) to 0.41, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 0.93. This value is below the healthy minimum of 1.5. It has decreased from 1.00 (Mar 24) to 0.93, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.51 (Mar 24) to 0.49, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 4. It has increased from 1.30 (Mar 24) to 2.14, marking an increase of 0.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -6.26 (Mar 24) to 0.00, marking an increase of 6.26.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has increased from -27.54 (Mar 24) to 0.00, marking an increase of 27.54.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 127.54 (Mar 24) to 0.00, marking a decrease of 127.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -1.65. This value is below the healthy minimum of 3. It has decreased from -0.01 (Mar 24) to -1.65, marking a decrease of 1.64.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.67. This value is below the healthy minimum of 3. It has decreased from -0.85 (Mar 24) to -2.67, marking a decrease of 1.82.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,875.49. It has decreased from 2,574.29 (Mar 24) to 1,875.49, marking a decrease of 698.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has decreased from 5.62 (Mar 24) to 4.92, marking a decrease of 0.70.
- For EV / EBITDA (X), as of Mar 25, the value is -30.96. This value is below the healthy minimum of 5. It has increased from -9,580.53 (Mar 24) to -30.96, marking an increase of 9,549.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 106.26 (Mar 24) to 0.00, marking a decrease of 106.26.
- For Price / BV (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 5.64.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 3. It has decreased from 4.55 (Mar 24) to 3.47, marking a decrease of 1.08.
- For EarningsYield, as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from -0.02 (Mar 24) to -0.10, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astec Lifesciences Ltd:
- Net Profit Margin: -35.32%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -20.22% (Industry Average ROCE: 15.21%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -57.4% (Industry Average ROE: 19.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.67
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.49
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 30.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.36
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -35.32%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Agro Chemicals/Pesticides | Godrej One, 3rd Floor, Pirojshanagar, Mumbai Maharashtra 400079 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nadir B Godrej | Chairman |
| Mr. Burjis N Godrej | Managing Director |
| Mr. Balram Singh Yadav | Non Executive Director |
| Mr. Ashok V Hiremath | Non Executive Director |
| Dr. Ganapati Yadav | Independent Director |
| Mr. R R Govindan | Independent Director |
| Mr. Nandkumar Dhekne | Independent Director |
| Ms. Anjali Gupte | Independent Director |
FAQ
What is the intrinsic value of Astec Lifesciences Ltd?
Astec Lifesciences Ltd's intrinsic value (as of 06 February 2026) is ₹417.44 which is 34.77% lower the current market price of ₹640.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,426 Cr. market cap, FY2025-2026 high/low of ₹991/554, reserves of ₹392 Cr, and liabilities of ₹883 Cr.
What is the Market Cap of Astec Lifesciences Ltd?
The Market Cap of Astec Lifesciences Ltd is 1,426 Cr..
What is the current Stock Price of Astec Lifesciences Ltd as on 06 February 2026?
The current stock price of Astec Lifesciences Ltd as on 06 February 2026 is ₹640.
What is the High / Low of Astec Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Astec Lifesciences Ltd stocks is ₹991/554.
What is the Stock P/E of Astec Lifesciences Ltd?
The Stock P/E of Astec Lifesciences Ltd is .
What is the Book Value of Astec Lifesciences Ltd?
The Book Value of Astec Lifesciences Ltd is 186.
What is the Dividend Yield of Astec Lifesciences Ltd?
The Dividend Yield of Astec Lifesciences Ltd is 0.00 %.
What is the ROCE of Astec Lifesciences Ltd?
The ROCE of Astec Lifesciences Ltd is 12.9 %.
What is the ROE of Astec Lifesciences Ltd?
The ROE of Astec Lifesciences Ltd is 45.3 %.
What is the Face Value of Astec Lifesciences Ltd?
The Face Value of Astec Lifesciences Ltd is 10.0.